Hookipa Historical Balance Sheet

HOOK Stock

USD 1.21 0.04 3.20%

Trend analysis of Hookipa Pharma balance sheet accounts such as Other Current Liabilities of 9.3 M or Total Current Liabilities of 25.4 M provides information on Hookipa Pharma's total assets, liabilities, and equity, which is the actual value of Hookipa Pharma to its prevalent stockholders. By breaking down trends over time using Hookipa Pharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Hookipa Pharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Hookipa Pharma is a good buy for the upcoming year.

Hookipa Pharma Inventory

(505,942)

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hookipa Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.

About Hookipa Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Hookipa Pharma at a specified time, usually calculated after every quarter, six months, or one year. Hookipa Pharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Hookipa Pharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Hookipa currently owns. An asset can also be divided into two categories, current and non-current.

Hookipa Pharma Balance Sheet Chart

At this time, Hookipa Pharma's Non Currrent Assets Other are quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 139.4 M this year, although the value of Net Tangible Assets will most likely fall to about 66.6 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Hookipa Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Hookipa Pharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Hookipa Pharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Hookipa Pharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Hookipa Pharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Hookipa Pharma current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hookipa Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.At this time, Hookipa Pharma's Non Currrent Assets Other are quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 139.4 M this year, although the value of Net Tangible Assets will most likely fall to about 66.6 M.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	6.5M	6.6M	875K	831.3K
Total Assets	170.5M	161.3M	82.5M	139.4M

Short Long Term Debt Total Total Assets

Hookipa Pharma balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab
Total Assets		0.64	0.77	0.79	0.9	0.4	0.87	0.75	0.72	-0.81	-0.59	0.65	0.8	0.77	0.7	0.57	-0.45	0.8	0.75	-0.79	-0.43	-0.69	0.77	0.61	0.71	-0.6
Short Long Term Debt Total	0.64		0.37	0.34	0.62	-0.35	0.54	0.85	0.25	-0.73	0.04	0.24	0.78	0.86	0.55	0.61	0.16	0.78	0.3	-0.48	0.19	-0.41	0.36	0.32	0.22	-0.43
Other Current Liab	0.77	0.37		0.95	0.83	0.71	0.87	0.69	0.84	-0.4	-0.88	0.8	0.4	0.7	0.63	0.13	-0.83	0.4	0.91	-0.72	-0.81	-0.82	0.95	0.92	0.92	-0.72
Total Current Liabilities	0.79	0.34	0.95		0.82	0.73	0.81	0.64	0.93	-0.47	-0.88	0.9	0.45	0.66	0.67	0.2	-0.79	0.45	0.88	-0.76	-0.78	-0.8	0.91	0.83	0.95	-0.68
Total Stockholder Equity	0.9	0.62	0.83	0.82		0.41	0.91	0.69	0.71	-0.63	-0.65	0.7	0.63	0.73	0.91	0.58	-0.44	0.63	0.78	-0.75	-0.41	-0.93	0.83	0.83	0.78	-0.89
Other Liab	0.4	-0.35	0.71	0.73	0.41		0.51	0.05	0.71	-0.02	-0.91	0.65	-0.03	0.06	0.23	-0.23	-0.93	-0.03	0.68	-0.39	-0.93	-0.5	0.69	0.61	0.77	-0.37
Net Tangible Assets	0.87	0.54	0.87	0.81	0.91	0.51		0.65	0.61	-0.62	-0.75	0.74	0.62	0.67	0.71	0.49	-0.57	0.62	0.9	-0.75	-0.55	-0.81	0.94	0.83	0.84	-0.75
Property Plant And Equipment Net	0.75	0.85	0.69	0.64	0.69	0.05	0.65		0.62	-0.69	-0.28	0.45	0.72	1.0	0.52	0.4	-0.27	0.72	0.58	-0.67	-0.25	-0.51	0.61	0.53	0.51	-0.45
Current Deferred Revenue	0.72	0.25	0.84	0.93	0.71	0.71	0.61	0.62		-0.46	-0.74	0.73	0.44	0.63	0.57	0.1	-0.72	0.44	0.7	-0.62	-0.71	-0.68	0.75	0.67	0.82	-0.55
Net Debt	-0.81	-0.73	-0.4	-0.47	-0.63	-0.02	-0.62	-0.69	-0.46		0.15	-0.34	-1.0	-0.69	-0.43	-0.63	0.03	-1.0	-0.4	0.46	0.0	0.32	-0.47	-0.21	-0.37	0.26
Retained Earnings	-0.59	0.04	-0.88	-0.88	-0.65	-0.91	-0.75	-0.28	-0.74	0.15		-0.85	-0.11	-0.3	-0.49	0.01	0.93	-0.11	-0.88	0.63	0.93	0.72	-0.88	-0.82	-0.93	0.6
Accounts Payable	0.65	0.24	0.8	0.9	0.7	0.65	0.74	0.45	0.73	-0.34	-0.85		0.33	0.47	0.65	0.29	-0.69	0.33	0.87	-0.79	-0.7	-0.72	0.85	0.72	0.94	-0.61
Cash	0.8	0.78	0.4	0.45	0.63	-0.03	0.62	0.72	0.44	-1.0	-0.11	0.33		0.72	0.44	0.64	0.01	1.0	0.39	-0.47	0.03	-0.32	0.47	0.22	0.35	-0.27
Non Current Assets Total	0.77	0.86	0.7	0.66	0.73	0.06	0.67	1.0	0.63	-0.69	-0.3	0.47	0.72		0.58	0.44	-0.26	0.72	0.6	-0.7	-0.25	-0.55	0.63	0.56	0.54	-0.49
Non Currrent Assets Other	0.7	0.55	0.63	0.67	0.91	0.23	0.71	0.52	0.57	-0.43	-0.49	0.65	0.44	0.58		0.65	-0.21	0.44	0.61	-0.69	-0.2	-0.92	0.62	0.72	0.65	-0.93
Other Assets	0.57	0.61	0.13	0.2	0.58	-0.23	0.49	0.4	0.1	-0.63	0.01	0.29	0.64	0.44	0.65		0.3	0.64	0.36	-0.6	0.3	-0.39	0.29	0.15	0.26	-0.43
Long Term Debt	-0.45	0.16	-0.83	-0.79	-0.44	-0.93	-0.57	-0.27	-0.72	0.03	0.93	-0.69	0.01	-0.26	-0.21	0.3		0.01	-0.76	0.47	1.0	0.51	-0.77	-0.7	-0.8	0.37
Cash And Short Term Investments	0.8	0.78	0.4	0.45	0.63	-0.03	0.62	0.72	0.44	-1.0	-0.11	0.33	1.0	0.72	0.44	0.64	0.01		0.39	-0.47	0.03	-0.32	0.47	0.22	0.35	-0.27
Net Receivables	0.75	0.3	0.91	0.88	0.78	0.68	0.9	0.58	0.7	-0.4	-0.88	0.87	0.39	0.6	0.61	0.36	-0.76	0.39		-0.86	-0.75	-0.75	0.96	0.83	0.96	-0.65
Common Stock Shares Outstanding	-0.79	-0.48	-0.72	-0.76	-0.75	-0.39	-0.75	-0.67	-0.62	0.46	0.63	-0.79	-0.47	-0.7	-0.69	-0.6	0.47	-0.47	-0.86		0.49	0.64	-0.75	-0.6	-0.78	0.55
Long Term Debt Total	-0.43	0.19	-0.81	-0.78	-0.41	-0.93	-0.55	-0.25	-0.71	0.0	0.93	-0.7	0.03	-0.25	-0.2	0.3	1.0	0.03	-0.75	0.49		0.49	-0.75	-0.68	-0.8	0.34
Non Current Liabilities Total	-0.69	-0.41	-0.82	-0.8	-0.93	-0.5	-0.81	-0.51	-0.68	0.32	0.72	-0.72	-0.32	-0.55	-0.92	-0.39	0.51	-0.32	-0.75	0.64	0.49		-0.8	-0.93	-0.8	0.98
Capital Surpluse	0.77	0.36	0.95	0.91	0.83	0.69	0.94	0.61	0.75	-0.47	-0.88	0.85	0.47	0.63	0.62	0.29	-0.77	0.47	0.96	-0.75	-0.75	-0.8		0.89	0.96	-0.7
Other Current Assets	0.61	0.32	0.92	0.83	0.83	0.61	0.83	0.53	0.67	-0.21	-0.82	0.72	0.22	0.56	0.72	0.15	-0.7	0.22	0.83	-0.6	-0.68	-0.93	0.89		0.85	-0.89
Other Stockholder Equity	0.71	0.22	0.92	0.95	0.78	0.77	0.84	0.51	0.82	-0.37	-0.93	0.94	0.35	0.54	0.65	0.26	-0.8	0.35	0.96	-0.78	-0.8	-0.8	0.96	0.85		-0.69
Total Liab	-0.6	-0.43	-0.72	-0.68	-0.89	-0.37	-0.75	-0.45	-0.55	0.26	0.6	-0.61	-0.27	-0.49	-0.93	-0.43	0.37	-0.27	-0.65	0.55	0.34	0.98	-0.7	-0.89	-0.69

Click cells to compare fundamentals

Hookipa Pharma Account Relationship Matchups

Hookipa Pharma balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	187.8M	126.0M	170.5M	161.3M	82.5M	139.4M
Short Long Term Debt Total	10.5M	10.6M	6.5M	6.6M	875K	831.3K
Other Current Liab	6.4M	11.6M	13.4M	11.7M	10.7M	9.3M
Total Current Liabilities	21.1M	27.7M	35.6M	42.0M	24.7M	25.4M
Total Stockholder Equity	156.1M	89.6M	102.5M	89.9M	51.2M	83.7M
Other Liab	1.9M	1.9M	2.7M	29.1M	33.4M	35.1M
Net Tangible Assets	117.9M	156.1M	89.6M	102.5M	117.9M	66.6M
Property Plant And Equipment Net	14.0M	22.1M	22.0M	13.2M	1.1M	1.0M
Current Deferred Revenue	4.6M	6.2M	16.0M	14.7M	4.8M	8.0M
Net Debt	(132.7M)	(56.3M)	(106.9M)	(110.5M)	(38.8M)	(40.7M)
Retained Earnings	(147.1M)	(222.8M)	(287.7M)	(369.3M)	(412.8M)	(392.1M)
Accounts Payable	8.0M	8.8M	5.5M	12.5M	8.7M	6.8M
Cash	143.2M	66.9M	113.4M	117.1M	39.7M	37.7M
Non Current Assets Total	16.3M	23.9M	23.3M	14.2M	1.9M	1.8M
Non Currrent Assets Other	1.9M	1.4M	863K	1.0M	816K	1.2M
Other Assets	10.1M	1.8M	1.3M	1.0	0.9	0.86
Long Term Debt	3.5M	4.5M	2.2M	911K	819.9K	778.9K
Cash And Short Term Investments	143.2M	66.9M	113.4M	117.1M	39.7M	37.7M
Net Receivables	20.7M	21.2M	22.0M	19.3M	23.7M	17.6M
Common Stock Shares Outstanding	2.6M	3.3M	6.6M	9.5M	12.5M	8.5M
Long Term Debt Total	3.9M	4.5M	2.2M	911K	819.9K	778.9K
Liabilities And Stockholders Equity	187.8M	126.0M	170.5M	161.3M	82.5M	139.4M
Non Current Liabilities Total	10.6M	8.8M	32.3M	29.5M	6.7M	6.3M
Capital Surpluse	225.6M	309.3M	317.1M	397.3M	457.0M	230.1M
Other Current Assets	8.1M	15.0M	12.7M	10.7M	17.3M	12.1M
Other Stockholder Equity	309.3M	317.1M	397.3M	467.0M	469.1M	295.9M
Total Liab	31.7M	36.5M	67.9M	71.5M	31.3M	40.5M
Net Invested Capital	160.7M	94.6M	105.0M	91.0M	51.2M	87.3M
Property Plant And Equipment Gross	14.0M	28.5M	29.8M	23.0M	7.0M	6.6M
Total Current Assets	171.5M	102.1M	147.2M	147.1M	80.7M	125.0M
Accumulated Other Comprehensive Income	(6.1M)	(4.8M)	(7.2M)	(7.9M)	(5.1M)	(5.3M)
Non Current Liabilities Other	1.4M	2.6M	31.4M	6.0M	5.6M	7.7M
Net Working Capital	150.4M	74.5M	111.6M	105.1M	56.0M	99.6M
Property Plant Equipment	14.6M	14.0M	16.4M	18.0M	20.7M	13.0M
Capital Lease Obligations	6.0M	5.6M	4.0M	5.4M	875K	831.3K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Hookipa Pharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Hookipa Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Hookipa Pharma Stock. Highlighted below are key reports to facilitate an investment decision about Hookipa Pharma Stock:

How To Invest In Hookipa

Details

Is Hookipa Stock a good investment?

Details

What is Hookipa Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.

You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hookipa Pharma. If investors know Hookipa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hookipa Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.47)

Revenue Per Share

3.505

Quarterly Revenue Growth

(0.82)

Return On Assets

(0.23)

Return On Equity

(0.62)

The market value of Hookipa Pharma is measured differently than its book value, which is the value of Hookipa that is recorded on the company's balance sheet. Investors also form their own opinion of Hookipa Pharma's value that differs from its market value or its book value, called intrinsic value, which is Hookipa Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hookipa Pharma's market value can be influenced by many factors that don't directly affect Hookipa Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Hookipa Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hookipa Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hookipa Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Hookipa Historical Balance Sheet

Hookipa Pharma Inventory

(505,942)

About Hookipa Balance Sheet Analysis

Hookipa Pharma Balance Sheet Chart

Total Assets

Total Current Liabilities

Hookipa Pharma balance sheet Correlations

Hookipa Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Hookipa Pharma balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Long Term Debt Total	+ 1.0	Long Term Debt
Total Liab	+ 0.98	Non Current Liabilities Total
Capital Surpluse	+ 0.96	Net Receivables
Other Stockholder Equity	+ 0.96	Net Receivables

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Other Current Assets	- 0.93	Non Current Liabilities Total
Total Liab	- 0.93	Non Currrent Assets Other
Other Stockholder Equity	- 0.93	Retained Earnings
Long Term Debt Total	- 0.93	Other Liab